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Abstract
AKI is one of the most serious complications of leptospirosis, an important zoonosis in the
tropics. Recently, NGAL, one of the novel AKI biomarkers, is extensively studied in various
specific settings such as sepsis, cardiac surgery, and radiocontrast nephropathy. In this
multicenter study, we aimed to study the role of NGAL as an early marker and an outcome
predictor of leptospirosis associated AKI. Patients who presented with clinical suspicious-
ness of leptospirosis were prospectively enrolled in 9 centers from August 2012 to Novem-
ber 2014. The first day of enrollment was the first day of clinical suspicious leptospirosis.
Blood and urine samples were serially collected on the first three days and day 7 after
enrollment. We used three standard techniques (microscopic agglutination test, direct cul-
ture, and PCR technique) to confirm the diagnosis of leptospirosis. KDIGO criteria were
used for AKI diagnosis. Recovery was defined as alive and not requiring dialysis during hos-
pitalization or maintaining maximum KDIGO stage at hospital discharge. Of the 221
recruited cases, 113 cases were leptospirosis confirmed cases. Thirty seven percent devel-
oped AKI. Median uNGAL and pNGAL levels in those developing AKI were significantly
higher than in patients not developing AKI [253.8 (631.4) vs 24.1 (49.6) ng/ml, p < 0.001]
and [1,030 (802.5) vs 192.0 (209.0) ng/ml, p < 0.001], respectively. uNGAL and pNGAL lev-
els associated with AKI had AUC-ROC of 0.91, and 0.92, respectively. Both of urine NGAL
and pNGAL level between AKI-recovery group and AKI-non recovery were comparable.
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From this multicenter study, uNGAL and pNGAL provided the promising result to be a
marker for leptospirosis associated AKI. However, both of them did not show the potential
role to be the predictor of renal recovery in this specific setting.
Introduction
Leptospirosis is an important zoonosis especially in the tropics. However, with the impact of
world globalization, there are also reports of this disease as sporadic cases in developed coun-
tries. A recent report has shown the annual incidence of leptospirosis in Thailand was 48.9 per
million population, thus ranking 7th in the world in terms of incidence [1].
Acute Kidney Injury (AKI) is one of the most serious complication of leptospirosis. The
incidence of AKI in leptospirosis by using the RIFLE AKI criteria was up to 84% [2]. This is
higher than the average AKI incidence in the Intensive Care Unit (ICU) [3] and more than
twice as high as seen in patients with community acquired pneumonia in the US [4]. In this
specific setting the kidney is injured by direct effects (direct invasion of the organism) and by
indirect effects such as dehydration, rhabdomyolysis, and hemorrhagic shock [5]. One of the
most robust biomarkers for AKI is neutrophil gelatinase associated lipocalin (NGAL). Previous
studies have used NGAL as an early marker of AKI [6] and as an outcome predictor [7,8].
However, only one study explored the role of NGAL in leptospirosis patients [9]. Benefits from
biomarkers to predict AKI in leptospirosis would include early triage patients from primary
hospital to tertiary care facilities, early treatment interventions such as fluid resuscitation, opti-
mizing tissue oxygenation and perfusion possibly preventing AKI progression, and finally,
early discontinuation of nephrotoxic drugs.
We conducted a prospective observational study to measure NGAL in urine and plasma of
hospitalized patients suspected of having leptospirosis. Using the KDIGO criteria to classify
AKI status [10], first, we analyzed baseline characteristics between AKI patients and non AKI
patients. Second, we compared the differences in urine and plasma NGAL (uNGAL, pNGAL)
concentration by AKI and renal recovery status. Third, we examined whether uNGAL and
pNGAL level associated with AKI and predicted renal non-recovery in a multivariable model
adjusting for clinical parameters.
Materials and Methods
Ethics statement
Study protocol was approved by The Institutional Review Board of Faculty of Medicine, Chula-
longkorn University, and The Institutional Review Board of Ministry of Public Health of Thai-
land. All participants accepted the protocol and provided written informed consent.
Patients and study design
This study was a multicenter, prospective, cohort study of patients presenting with clinical sus-
picion of leptospirosis. All the cases were hospitalized. Specific inclusion criteria included high
fever (BT higher than 38°c), severe myalgia, and history of exposure to reservoir animals. The
patients need to be first admitted into the participating centers, not referring from the non-par-
ticipating centers. We excluded the patients who suffered from known other infectious disease.
This study was conducted in 9 centers in 8 provinces around Thailand during August 2012 to
November 2014. Of the nine participating hospitals, 2 centers were from the Northern part, 3
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centers from the Northeastern part, 1 center from the Eastern part and the other three centers
from the Southern part. For the level of care, 2 centers were the referral/tertiary care hospital, 7
centers were the provincial hospital. Blood and urine were serially collected on the first three
days after study enrollment and on day 7.
Sample collection and Biomarkers assay. A 12-ml blood sample was taken and well
mixed on the day 1, day 2, day 3 and day 7 after enrollment. The first day of enrollment was
the first day of clinical suspicious leptospirosis. A 30-ml urine sample was obtained on the
same day. Urine samples were poured into 50-ml conical centrifuge tubes. Both of plasma and
urine were centrifuged for 10 minutes at 1000 G at 4°C, and frozen at -20°C until shipped to
the central laboratory. Samples were then stored at -80°C until analyzed. uNGAL was mea-
sured by ELISA (R&D, Minneapolis, MN, USA), following the manufacturers’ instructions.
Plasma NGAL was tested using the Triage NGAL kit (Alere, San Diego, CA, USA). Both bio-
markers were tested on the first day of enrollment. All samples were analyzed in duplicate.
Definitions. We used three standard techniques; microscopic agglutination test (MAT),
direct culture, and PCR technique, to confirm leptospirosis. In brief, MAT was performed by
using the standard protocol of the World Health Organization (WHO) guideline [11]. A posi-
tive MAT was defined as a single serum titer of>1:100 or a 4-fold rise in pair serum. We used
the single serum cut point of> 1:100 based on previous study [12]. For direct culture of lepto-
spires, one drop of whole blood was cultured into 4 mL liquid Ellinghausen–McCullough–
Johnson–Harris (EMJH) at 29°C for 2 weeks. Detection for leptospires was accomplished by
direct observation using Dark-field microscopy. For PCR technique, DNA was extracted from
urine samples using a High Pure PCR Template Preparation kit (Roche Diagnostics, Ger-
many). The two primers used for amplification of LipL 32 gene were as follows 45F primers
(5’ AAG CAT TAC CGC TTG TGG TG3’) and 287R primers (5’ CGA ACT CCC ATT TCA GCG
AT 3’), PCR reactions of urine samples were performed in a final volume of 20 μl, correspond-
ing to 2 μl of genomic DNA and 18 μl of reaction mix containing 25 mM of each dNTP; 0.1 μl
of Taq DNA polymerase; 0.4 μl of each primer in 25 mMMgCl2 and 10x KCl under 13.5 μl
DW. The PCR program consisted of an initial cycle of 94°C for 10 min, followed by 40 cycles
of 94°C for 1 min, 55°C for 1 min and 72°C for 1 min and a final extension step at 72°C for 7
min. PCR products were run on a 1% agarose gel with ethidium bromide and photographed.
We used the term “All cases” for patients who were clinical suspicious of leptospirosis and
were enrolled into the cohort. “Leptospirosis cases” were defined if any one of the above tests
were positive.
We used KDIGO guideline to classify AKI status [10]. Due to the limitation of urine output
data, we use only serum creatinine criteria. Definitions of the baseline serum creatinine was the
lowest value between the a. the first creatinine recorded on the day of hospital admission or 2)
the back calculation from the Modification on Diet in Renal Disease (MDRD) equation for
equation for serum creatinine using a GFR of 75mL/min/1.73m2 [13].
Recovery was defined as alive and not requiring dialysis during hospitalization and not hav-
ing a persistent KDIGO stage at hospital discharge (i.e. patients had to improve by at least one
KDIGO stage to be considered as recovery) [7,13].
Statistical analyses
Clinical characteristics and biomarkers on the day of enrollment were compared between
patients with AKI and those without AKI and between renal recovery patients and non-recov-
ery patients at hospital discharge time. Categorical data were expressed as proportions and
compared using a Chi-square test. Continuous data were expressed as mean ± standard devia-
tion and compared using the student’s t-test or were expressed as median ± intra-quartile
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range (IQR) and compared using Mann-Whitney U test, as appropriate. We fitted an inclusive
logistic regression model using biomarkers to predict the probability of AKI and recovery from
AKI, and expressed these results as odds ratios (OR), and 95% confidence intervals (CI). To
assess the predictive ability of single and multiple biomarkers, receiver operating characteristic
(ROC) curves were generated and the area under the curve (AUC) was calculated. Statistical
analyses were performed using SPSS version 17.0 and GraphPad PRISM version 5.1. P
values< 0.05 were considered to indicate statistical significance.
Results
Patients clinical characteristics
Of the 221 subjects with clinical suspicion of leptospirosis (all cases), urine samples were
unavailable in 10. These cases and 5 additional patients that could not be identified for AKI sta-
tus were excluded (Fig 1). Of the remaining 206, 55 (26%) were diagnosed with AKI. Of the 55
cases of AKI, 7.3% had KDIGO stage1, 16.4% had KDIGO stage2, and 76.4% had KDIGO
stage3. AKI patients had the recovery rate at 81.8% (Fig 1). Twenty nine percent of AKI
patients required dialysis support. AKI patients had mortality rate 10.1% while non-AKI
patients had only 0.6%. AKI patients had lower body temperature, more leukocytosis, lower
hemoglobin, more thrombocytopenia, higher bilirubin (TB/DB), higher SGOT/SGPT, and
lower sodium than non-AKI patients (Table 1).
The diagnosis of leptospirosis was confirmed in 113 patients (54.9%), and about one third
(37.2%) developed AKI. Of the 42 AKI cases, most of them had KDIGO stage 3 (33 cases,
Fig 1. Subject disposition for the lepto Thai study cohort.
doi:10.1371/journal.pone.0143367.g001
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78.6%), followed by KDIGO stage 2 (7 cases, 16.7%), and KDIGO stage 1 (2 cases. 4.7%).
Twenty four percent of AKI patients need dialysis support. The mortality rate in AKI patients
was 9.5% and no one in non-AKI patients was died. Again, Leptospirosis patients who devel-
oped AKI were likely to have more leukocytosis, more thrombocytopenia, lower hemoglobin,
more thrombocytopenia, higher bilirubin level, and higher serum glutamic oxaloacetic trans-
aminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) than non-AKI patients
(Table 1).
By contrast, only 13 from the 93 (14.0%) non-leptospirosis patients, developed AKI (Fig 1).
Of the 13 AKI cases, 15.4% had KDIGO stage1 and KDIGO stage 2. While 69.2% had KDIGO
stage 3. Forty six percent of AKI patients required dialysis support. AKI patient had higher
mortality rate than non-AKI patients, 15.4% vs 1.2%. Patients with AKI had lower diastolic
blood pressure, more thrombocytopenia, higher bilirubin (TB/DB), and higher SGOT than
non-AKI patients (Table 1).
Biomarker concentrations by AKI and recovery status
First, focusing on all patients with suspected Leptospirosis, AKI patients had significantly
higher urine and plasma NGAL (uNGAL, pNGAL) than non-AKI patients on the 1st day of
enrollment, uNGAL; AKI vs non-AKI 435.5 ng/ml (interquartile range (IQR) 918.6) vs 18.3
Table 1. Patient characteristics by AKI status on the first day of enrollment into the study.
Characteristic All cases (n = 206) Leptospirosis cases (n = 113, 54.9%) Non-leptospirosis cases (n = 93,
45.1%)
AKI (n = 55,
26.7%)
Non-AKI
(n = 151)
P-
value
AKI (n = 42,
37.1%)
Non-AKI
(n = 71)
p-
value
AKI (n = 13,
14.0%)
Non-AKI
(n = 80)
p-
value
Gender, Male (%) 44(81.5) 119(78.3) 0.70 35(85.4) 59(81.9) 0.80 9(69.2) 60(75.0) 0.74
Fever day, days 4.5(2.1) 3.9(2.4) 0.08 4.7(2.2) 3.8(2.6) 0.21 3.6(1.6) 3.94(2.3) 0.65
Age, years 46.3(17.1) 41.6(14.8) 0.06 43.0(12.9) 36.6(11.1) 0.17 46.1(22.6) 35.3(16.2) 0.28
Body temperature,
°c
37.1(2.2) 38.4(1.1) 0.001 37.4(1.1) 38.0(1.1) 0.07 36.3(4.0) 38.78(1.1) 0.003
SBP, mmHg 107.8(21.2) 111.7(20.0) 0.30 109.1(22.9) 110.2(18.6) 0.89 104.1(16.2) 114.9(21.9) 0.06
DBP, mmHg 64.6(15.0) 68.9(12.9) 0.06 65.4(15.2) 68.8(13.2) 0.35 62.3(14.9) 69.5(13.1) 0.039
Creatinine, mg/dL 5.0(1.9) 1.0(0.3) 0.009 5.1(2.2) 1.0(0.6) <0.001 4.1(3.5) 0.9(0.4) <0.001
WBC x 103/uL 12.7(10.6) 7.9(4.9) <0.001 13.3(9.8) 7.9(8.1) 0.002 9.3(10.6) 7.7(5.1) 0.10
Hgb, g/dL 11.3(2.9) 12.4(3.4) <0.001 11.0(1.9) 11.6(2.8) 0.019 13.2(3.2) 12.2(2.0) 0.56
Platelet x 103/uL 88.6(85.5) 166.8(114.0) 0.001 39.0(91.0) 150.5(90.3) <0.001 68.5(109.0) 139.0(117.3) 0.002
TB, mg/dL 4.0(6.9) 1.2(2.9) <0.001 4.3(13.1) 1.2(3.7) 0.007 3.9(4.4) 1.3(1.5) 0.04
DB, mg/dL 2.3(4.9) 0.3(1.3) <0.001 2.3(5.5) 0.3(1.4) <0.001 2.0(3.1) 0.5(0.7) 0.007
SGOT, u/L 61(124) 49(71) <0.001 58(75) 49(81) 0.037 544(2770) 47(85) 0.03
SGPT, u/L 64(87) 46(70) 0.009 61(80) 46(80) 0.05 209(5393) 44(83) 0.09
Na, mEq/L 133.0(8) 135.0(7) 0.023 134.8(4.4) 134.5(4.1) 0.61 134.5(5.8) 128.6(28.7) 0.51
K, mEq/L 4.0(1.1) 3.5(0.5) 0.56 3.8(0.5) 3.6(0.6) 0.28 4.6(1.9) 3.36(0.5) 0.09
HCO3
−, mEq/L 19.0(4.4) 22.1(7.0) 0.06 19.8(4.3) 22.0(7.5) 0.28 16.5(4.0) 21.9(6.6) 0.001
RRT (%) 16(29) 0 10(24) 0 6(46) 0
SBP: systolic blood pressure, DBP: diastolic blood pressure, WBC: white blood cell, Hgb: hemoglobin, TB: total bilirubin, DB: direct bilirubin, SGOT:
Serum Glutamic Oxaloacetic Transaminase, SGPT: Serum Glutamic, Pyruvic Transaminase, HCO3
−: bicarbonate
Values in the table is mean (s.d.) for Fever day, Age, Body temperature, SBP, DBP, Hgb, Na, K, HCO3; median (IQR) for Creatinine, WBC, Platelet, TB,
DB, SGOT, SGPT and count (%) for Gender, and RRT, RRT: renal replacement therapy.
doi:10.1371/journal.pone.0143367.t001
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ng/ml (IQR 39.9), P< 0.001, pNGAL: AKI vs non-AKI 1,015 ng/ml (IQR 919.8) vs 124.0 ng/
ml (IQR 166.0), P< 0.001 (Fig 2A and 2B). However, neither uNGAL nor pNGAL were signif-
icantly different between patients recovering from versus those not recovery: uNGAL recovery
vs non-recovery 435.5 ng/ml (IQR 904.0) vs 501.4 (IQR 1499.9) ng/ml, P = 0.78; pNGAL
recovery vs non-recovery 993.0 ng/ml (IQR 895.0) vs 1160.0 ng/ml (IQR 1056.5), P = 0.91 (Fig
3A and 3B).
When we restricted the analysis to patients without evidence of AKI (i.e. normal creatinine)
on enrollment (4 of 55 cases), uNGAL was still significantly higher than in patients not devel-
oping AKI: 1199.9 ng/ml (IQR 3141.75.) vs 19.52 ng/ml (IQR 39.94), P = 0.005. However the
level of pNGAL between these two group was comparable: 385.5 ng/ml (IQR 628.0) vs 161 ng/
ml (IQR 169.8), P = 0.68.
For patients with confirmed leptospirosis, median uNGAL and pNGAL on the 1st day of
enrollment were also significantly higher for patients with AKI: uNGAL, AKI vs non-AKI
253.8 ng/ml (IQR 631.4) vs 24.1 ng/ml (IQR 49.6), P< 0.001; pNGAL, AKI vs non-AKI 1,030
(IQR 802.5) vs 192.0 (IQR 209.0), P< 0.001 (Fig 2A and 2B). However, again patients
Fig 2. Urine and plasma neutrophil gelatinase-associated lipocalin (NGAL) concentration stratified by AKI status.
doi:10.1371/journal.pone.0143367.g002
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recovering from AKI did not demonstrate differences in median uNGAL or pNGAL concen-
trations compared to those not recovering: recovery vs non-recovery, uNGAL, 253.8 ng/ml
(IQR 615.4) vs 531.8 ng/ml (IQR 1754.3), P = 0.65; pNGAL, 1030.0 (IQR 802.5) vs 192.0 (IQR
209.0), P = 0.93.
For patients without leptospirosis, we also demonstrated the higher median uNGAL and
pNGAL concentrations among those with AKI: uNGAL (140.3 ng/ml (IQR 4667.7) compared
with those without (15.1 ng/ml (IQR 21.0), P< 0.001, pNGAL: AKI vs non-AKI 725.0 ng/ml
(IQR 994.0) vs 97.5 ng/ml (IQR 137.0), P< 0.001 (Fig 2A and 2B). Neither biomarker discrim-
inated between recovery and non-recovery.
When comparing between leptospirosis AKI and non-leptospirosis AKI, the median
uNGAL and pNGAL of leptospirosis AKI and non-leptospirosis AKI were comparable,
P = 0.09 and P = 0.40, respectively (Fig 2A and 2B).
We have also stratified the level of biomarkers by day of fever (first 3 days, and after day 3 of
fever) to decrease the lead time bias. For all cases, we significantly found uNGAL and pNGAL
level of AKI group higher than non-AKI group on the first three day of fever (P< 0.001,
P< 0.001, respectively). From day 4 after onset of fever, both uNGAL and pNGAL still showed
the higher level in AKI group than in non-AKI group (P< 0.001, P< 0.001, respectively)
(Table 2A). Neither uNGAL nor pNGAL exhibited differences between recovery and non-
recovery groups at any study period. For the leptospirosis confirmed patients and non-lepto-
spirosis patients, we also found found uNGAL and pNGAL level of AKI group higher than
non-AKI group on the first three day of fever and after day 3 of fever (Table 2B and 2C).
Again, we did not found significant difference of uNGAL or pNGAL exhibited between recov-
ery and non-recovery groups at any study period.
Biomarkers for diagnosis of AKI and prediction renal recovery
Fig 3A illustrated the ROC curves for uNGAL and pNGAL. For diagnosis AKI in all cases (lep-
tospirosis suspected cases) the area under the ROC curve (AUC) was 0.94 (95% confidence
interval (CI) 0.90–0.97) for uNGAL and 0.89 (95% 0.84–0.95) for pNGAL. The AUCs for
uNGAL and pNGAL for prediction of renal non-recovery in all cases were 0.53 (95% CI 0.33–
0.74) and 0.49 (95% CI 0.23–0.76), respectively. For diagnosis AKI, we chose the cut-off which
provided the maximum summation of sensitivity and specificity. The sensitivity and specificity
together were maximized at the 78.2 ng/ml cut-off for uNGAL and at the 296.5 ng/ml cut-off
for pNGAL (Table 3A). Focusing on the predicting model for AKI and renal recovery in all
cases, we found uNGAL and pNGAL independently associated with AKI, odds ratio (OR) 18.1
(95% CI 2.0–160.5), P = 0.009, and OR 1.59 (1.28–1.97), P< 0.001, respectively) (Table 4A).
Neither uNGAL nor pNGAL were predictive of renal non-recovery in the adjusted model. We
ran a stepwise analysis combining uNGAL and pNGAL in order to assess the discriminatory
effects of these biomarkers in association with AKI and predicting renal recovery. The model
comprising two biomarkers (Fig 3A) didn’t increase the association between NGAL and AKI
with AUC of 0.94 (0.90–0.98). Again, the combined biomarker model didn’t improve the pre-
diction of renal non-recovery with AUC of 0.55 (95% CI 0.31–0.79). To improve the prediction
of renal outcome, we have combined the clinical parameters including body temperature and
systolic blood pressure with the uNGAL and pNGAL. We found the improvement of predic-
tion with the AUC of 0.80 (0.44,1.00) (S1 Table).
For the association between NGAL and AKI in leptospirosis cases, the AUC-ROC was 0.91 for
uNGAL, and 0.92 for pNGAL (Fig 3B). The best cut-off for diagnosis AKI was 78.2 ng/ml for
uNGAL, and 327 ng/ml for pNGAL (Table 3B). In the adjusted model, we found uNGAL and
pNGAL independently associated with AKI, OR 14.1, P = 0.023, and OR 1.45, P< 0.001,
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respectively (Table 4B). Neither uNGAL nor pNGAL were predictive of renal non-recovery in the
adjusted model. In a stepwise analysis combining uNGAL and pNGAL in association with AKI,
the combining two biomarkers didn’t increase the association with AKI, AUC of 0.91 (Fig 3B).
For the association between NGAL and AKI in non-leptospirosis cases, the AUC-ROC was
0.96 for both uNGAL and pNGAL (Fig 3C). The best cut off for diagnosis AKI was 44.0 ng/ml
for uNGAL and 185.5 ng/ml for pNGAL (Table 3C). In the adjusted model, we found only
pNGAL independently associated with AKI, OR 2.43, P = 0.015 (Table 4C). Neither uNGAL
nor pNGAL were predictive of renal non-recovery in the adjusted model. In a stepwise analysis
combining uNGAL and pNGAL in association with AKI, the combining two biomarkers
didn’t increase the association of biomarkers and AKI with AUC of 0.96 (Fig 3C).
Fig 3. The area under the curve (AUC) for the association between biomarkers and AKI: pNGAL alone, uNGAL alone, and combinedmodel.
doi:10.1371/journal.pone.0143367.g003
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Discussion
In this study, we found that both uNGAL and pNGAL concentrations were significantly higher
in patients with all cases (suspected leptospirosis), leptospirosis cases, and non-leptospirosis
cases, who developed AKI. Both biomarkers had good association with AKI on the first day of
presentation. In leptospirosis cases, uNGAL> 78.2 ng/ml and pNGAL> 327.0 ng/ml, associ-
ated with AKI by a sensitivity of 86.1% and 85.0% and specificity of 85.1% and 81.4% respec-
tively. Using these cutoffs, the positive (PPV) and negative predictive values (NPV) for
Table 2. Analysis of biomarkers stratified by day of fever between AKI and non-AKI (A) in all cases, (B) in leptospirosis cases, and (C) in non-lepto-
spirosis cases.
Biomarkers Day of fever AKI Non-AKI P-value
A. In all cases (n = 206)
uNGAL, ng/mL day 1 –day 3 179.4(4733.86) 16.1(35.94) <0.001
day 4 up 561.99(688.43) 21(48.02) <0.001
pNGAL, ng/mL day 1 –day 3 891.65(682) 102(131.5) <0.001
day 4 up 1300(644) 173(221.5) <0.001
Serum creatinine,,mg/dL day 1 –day 3 3.6(2.95) 0.96(0.32) <0.001
day 4 up 4.54(2.86) 0.88(0.38) <0.001
B. In leptospirosis cases (n = 113)
uNGAL, ng/mL day 1 –day 3 158.4(867.7) 20.8(45.7) <0.001
day 4 up 550.3(583.3) 23.2(64.4) <0.001
pNGAL, ng/mL day 1 –day 3 945(732) 111(134) 0.001
day 4 up 1300(593.5) 211.5(147.3) <0.001
Serum creatinine, mg/dL day 1 –day 3 3.6(2.95) 0.98(0.32) <0.001
day 4 up 5.1(2.5) 0.88(0.45) <0.001
C. In non-leptospirosis cases (n = 93)
uNGAL, ng/mL day 1 –day 3 4793.2(7941.5) 13.3(20.6) 0.001
day 4 up 1403.1(2355.6) 16.8(17.7) <0.001
pNGAL, ng/mL day 1 –day 3 725(818.8) 97.5(134.25) 0.001
day 4 up 391(1112) 100(133.25) 0.002
Serum creatinine, mg/dL day 1 –day 3 2.36(3.68) 0.91(0.36) <0.001
day 4 up 4.22(5.28) 0.88(0.28) <0.001
doi:10.1371/journal.pone.0143367.t002
Table 3. Urine NGAL, plasma NGAL concentration at the best cut-off values for diagnosis AKI (A) in all cases, (B) in leptospirosis cases, and (C) in
non-leptospirosis cases.
Biomarkers cutoff, ng/mL Sensitivity Speciﬁcity PPV NPV
A. In all cases (n = 206)
uNGAL 78.2 0.848 0.884 0.709 0.946
pNGAL 296.5 0.852 0.841 0.657 0.941
B. In leptospirosis case (n = 113)
uNGAL 78.2 0.861 0.851 0.756 0.919
pNGAL 327 0.854 0.814 0.729 0.905
C. In non-leptospirosis cases (n = 93)
uNGAL 44 0.909 0.841 0.476 0.983
pNGAL 185.5 0.846 0.734 0.344 0.967
doi:10.1371/journal.pone.0143367.t003
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uNGAL were 75.6% and 91.9%, and for pNGAL were 72.9% and 90.5%. Moreover, uNGAL
and pNGAL remained strong association with AKI by a covariate-adjusted model. Combining
two markers together didn’t improve the association with AKI. Neither uNGAL nor pNGAL
were the predictors of renal recovery.
Table 4. Analysis of biomarkers associated with AKI (A) in all cases, (B) in leptospirosis cases, and C) in non-leptospirosis cases.
Biomarkers/Clinical Parameters Odds ratio (95%CI) unadjusted P-value Odds ratio(95%CI) adjusted P-value
A. For all patients (n = 206)
uNGAL x 100 ng/mL 2.58(1.68,3.95) <0.001 18.10(2.04,160.52)a 0.009
pNGAL x 100 ng/mL 1.48(1.33,1.64) <0.001 1.59(1.28,1.97) b <0.001
Serum creatinine x 0.1, mg/dL 1.27(1.17,1.39) <0.001
Body temperature, °c 0.67(0.51,0.88) 0.005 0.19(0.06)0.64 a 0.008
WBC x 5000/uL 1.10(1.04,1.16) 0.001
Hgb, g/dL 0.79(0.69,0.92) 0.002
Platelet x 10000/uL 0.88(0.84,0.93) <0.001 0.92(0.84,1.01) a 0.078
0.90(0.83,0.96) b 0.003
TB, mg/dL 1.08(1.01,1.62) 0.024
DB, mg/dL 1.15(1.02,1.29) 0.020
SGOT x 10, u/L 1.05(0.99,1.12) 0.088
SGPT x 10, u/L 1.01(1.00,1.02) 0.204
HCO3
−, mEq/L 0.94(0.89,0.99) 0.013 0.90(0.82,0.99) b 0.026
B. For leptospirosis cases (n = 113)
uNGAL x 100 ng/mL 2.58(1.68,3.95) <0.001 14.07(1.45,136.80) a 0.023
pNGAL x 100 ng/mL 1.40(1.25,1.58) <0.001 1.45(1.18,1.78) b <0.001
Serum creatinine x 0.1, mg/dL 1.20(1.11,1.30) <0.001
WBC x 5000/uL 1.12(1.03,1.21) 0.006
Hgb, g/dL 0.81(0.68,0.97) 0.023
Platelet x 10000/uL 0.91(0.86.0.96) 0.001 0.81(0.68,0.96) a 0.013
0.90(0.83,0.97) b 0.008
TB, mg/dL 1.07(1.00,1.16) 0.064
DB, mg/dL 1.16(1.00,1.34) 0.044
SGOT x 10, u/L 1.02(0.96,1.08) 0.575
SGPT x 10, u/L 1.00(0.99,1.02) 0.786
C. For non-leptospirosis cases (n = 93)
uNGAL x 100 ng/mL 2.11(0.99,4.48) 0.051 2.11(0.99,4.48)a 0.051
pNGAL x 100 ng/mL 1.58(1.25,2.02) <0.001 2.43(1.18,4.98)b 0.015
Serum creatinine x 0.1, mg/dL 3.2(1.01,10.2) 0.049
Body temperature, °c 0.19(0.42,1.04) 0.073
DBP 0.98(0.93,1.03) 0.379
Platelet x 10000/uL 0.9(0.83,0.98) 0.012
TB, mg/dL 1.02(0.89,1.22) 0.472
DB, mg/dL 1.02(0.85,1.33) 0.180
SGOT x 10, u/L 1.02(0.99,1.06) 0.112 1.02(0.99,1.03)b 0.157
HCO3-, mEq/L 0.18(0.48,0.81) <0.001
WBC: white blood cell, Hgb: hemoglobin, TB: total bilirubin, DB: direct bilirubin, SGOT: serum glutamic oxaloacetic transaminase, SGPT: serum glutamic,
pyruvic transaminase, HCO3
−: bicarbonate
a adjusted for uNGAL,
b adjusted for pNGAL.
doi:10.1371/journal.pone.0143367.t004
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To our knowledge, this is the largest study to examine the role of NGAL in AKI and renal
recovery for patients with suspected or confirmed leptospirosis. AKI can be a diagnostic chal-
lenge in patients with leptospirosis because serum creatinine may be interfered by many factors
such as volume overload, rhabdomyolysis, and jaundice. These confounding factors together
make serum creatinine less sensitive and specific in the setting of leptospirosis. Most of lepto-
spirosis patients live in rural areas and shortages of nephrologists and dialysis equipment are
common. Availability of specific novel biomarkers would accelerate the timing of AKI detec-
tion and triage the leptospirosis AKI patients to tertiary care hospitals. During the past few
years, uNGAL and pNGAL have been tested as markers for early diagnosis of AKI in various
setting: sepsis, ischemic, post-transplantation [14–21]. Associations between NGAL and clini-
cal and laboratory markers of severity such as WBC count, bilirubin level, or lower of platelet
count and AKI are not unexpected and corresponded with the previous studies [22,23].
In our cohort, there was no difference in median uNGAL levels between leptospirosis AKI
patients and non-leptospirosis AKI patients. Although the optimal cut-off for uNGAL (about
80 ng/ml) to diagnosis leptospirosis AKI in our study seemed to be a bit lower than the other
studies (usual cutoff for general septic AKI was 100–150 ng/ml) [24].
The higher sensitivity of uNGAL in diagnosis AKI in leptospirosis could be due to the fact
that leptospirosis directly invades distal tubule epithelium. We found that pNGAL was less
association with AKI than uNGAL (AUC 0.87 VS 0.92 for leptospirosis cases). This might be
explained by plasma NGAL can be produced in various organs such as liver, colon and lung
during the process of inflammation/infection [23]. Moreover, inflammatory cell like neutro-
phils, monocytes, and other immune-competent cells can also synthesized and release NGAL
into systemic circulation [25]. The last, declining of filtration rate during AKI may slow down
the elimination of systemic NGAL and result in the rising of concentrations of pNGAL [26].
There are several limitations to our study. First, due to the study design and variable timing
of hospital admission, we cannot test all patients from the first day of fever. Therefore most of
our patients had increased serum creatinine since the first day of enrollment. Therefore, the
interpretation of the result for the role of NGAL prediction leptospirosis AKI need to under-
stand this limitation. However, we have stratified patients by day of fever and still found that
the NGAL level was significantly higher in patients with AKI than in patients without. Second,
we have measured biomarkers at only a single time point (on the first day of enrollment) and
could not assess the value of uNGAL and pNGAL as repeated measures. Nevertheless, risk
stratification and prognostication using a biomarker is likely to be useful only when biomarker
concentrations are measured early. Third, we were unable to measure process of care variables
such as the effect of co-interventions on biomarkers and its influence on development of AKI.
Fourth, we found that uNGAL and pNGAL could not predict renal non-recovery. Our finding
should be interpreted with caution because the limitation number of patients in our study.
Only 10 patients from 55 AKI patients did not recover. However, it is notable that neither bio-
marker could predict recovery when we have observed reasonable performance for this indica-
tion in other patient populations including community-acquired pneumonia [7] and acute
renal failure receiving renal replacement therapy [8].
Our study has several strengths. First, the study design is a multicenter study testing bio-
markers in hospitalized patients with leptospirosis, therefore the results are highly applicable to
this specific population. Second, we chose the first day of presentation to medical attention
(the first day of clinical suspicious leptospirosis) as the time to test biomarkers. This time point
was match to real clinical situation. Because most of leptospirosis patients came to hospital on
various day of fever, so it was hard to test biomarkers only on the first day of fever. Third, we
have tested NGAL in plasma in addition to urine. This will solve the limitations of unavailable
urine sample which is a common situation in severe sepsis/septic shock. Moreover some
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interventions such as diuretic therapy and intravenous fluid might interfere with the level of
urine biomarkers.
In summary, uNGAL and pNGAL appears to be useful markers for detecting AKI in
patients with suspected leptospirosis. Our data suggest that neither uNGAL nor pNGAL
improves clinical risk prediction of renal non-recovery.
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